Jinwon Life Sciences Selected as Joint Research Institution for National Project Developing Platform to Respond to Emerging Infectious Diseases
[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 25th that its research on developing a new mRNA vaccine platform using circular mRNA vaccine technology has been selected as a detailed research project under the Ministry of Science and ICT's New and Re-emerging Infectious Disease Response Platform Technology Development Project, and it will participate as a joint research and development institution.
The overall project title is "Development of a Korean-style Nano-convergent mRNA Vaccine Platform Technology and Establishment of Efficacy Evaluation Technology for Infectious Disease X Response," with Korea University Sejong Campus as the lead research institution. The project consists of five detailed sub-projects, including mRNA vaccine platform development, mRNA vaccine delivery system development, self-assembling vaccine platform development, immune-responsive adjuvant development, and vaccine immune mechanism research.
GeneOne Life Science will be responsible for building the circular mRNA platform, production, and efficacy evaluation over a total of 43 months, as well as optimizing the large-scale mRNA production process and producing clinical-grade vaccines at cGMP standards.
A representative from GeneOne Life Science stated, "Circular mRNA has superior stability compared to conventional mRNA, does not require a capping process which simplifies the procedure, making raw material procurement easier and production yield higher." He added, "In particular, due to its excellent stability in the body, we are evaluating the possibility of replacing lipid nanoparticles (LNP), and we are currently preparing a patent application for this."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "Russia Launches Large-Scale Nuclear Drills During Putin's Visit to China"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Park Younggeun, CEO of GeneOne Life Science, said, "The status of mRNA vaccines as vaccines for new and re-emerging infectious diseases is increasingly rising." He continued, "By carrying out this project along with the existing mRNA vaccine platform and bulk production process we possess, we will develop and secure a circular mRNA vaccine platform to establish global competitiveness in the core technology field of mRNA vaccines."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
